Bolstered by the success of CAR T-cell therapy, research on the engineering of CAR-NK cells against MM is currently well underway; and preclinical data on CAR-NK against NKG2D ligands, CD38, and BCMA demonstrate potent and specific anti-MM cytotoxicity [153,154,155]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.